Ambu A/S

AMBU B

Equity

ISIN DK0060946788 / Valor 39639588

Nasdaq Copenhagen Equities (2024-09-16)

DKK 131.20-1.50%

Ambu A/S
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ambu A/S is a global company headquartered in Ballerup, Denmark, with a workforce spread across Europe, North America, Asia Pacific, and Latin America. Since 1937, the company has been focused on developing breakthrough ideas and solutions in collaboration with healthcare professionals to save lives and enhance patient care. Ambu specializes in providing a wide range of single-use medical devices, with a particular focus on endoscopy solutions in the fields of Pulmonology, Urology, ENT, and GI. The company's unique endoscopy systems, such as the Ambu® aView™ 2 Advance and the Ambu® aBox™ 2, support the needs of healthcare professionals in hospitals worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Revenue Growth

In the second quarter of the 2023/24 financial year, Ambu A/S reported a significant increase in revenue. The company achieved an organic revenue growth of 15.5%, amounting to DKK 1,367 million. This growth was notably driven by a strong performance in the Endoscopy Solutions sector, which saw a 22.3% increase in revenue.

EBIT Improvement

Ambu A/S demonstrated a robust improvement in earnings before interest and taxes (EBIT) during the second quarter. The EBIT before special items reached DKK 194 million, translating to an EBIT margin of 14.2%. This represents a substantial improvement from the previous year's margin of 3.9%, reflecting effective cost management and operational efficiency.

Free Cash Flow Increase

The company also saw a significant improvement in its free cash flow. For the quarter, Ambu A/S reported a free cash flow before acquisitions of DKK 128 million, a notable increase from DKK 21 million in the same quarter of the previous year. This improvement underscores the company's enhanced liquidity and financial health.

Outlook for 2023/24

Following the strong performance in the first half of the year, Ambu A/S has raised its financial outlook for the full year 2023/24. The company now expects an organic revenue growth of 10-12% and an EBIT margin before special items of 10-12%. Additionally, the forecast for free cash flow has been increased to DKK +370 million.

Strategic Developments

Ambu A/S continues to strengthen its market position with strategic regulatory approvals and product launches. Notably, the company received FDA clearance for its aScope™ Duodeno 2 and aBox™ 2, enhancing its gastroenterology offerings. These developments are expected to support sustained growth and market penetration in North America and other regions.

Summarized from source with an LLMView Source

Key figures

68.2%1Y

-38.6%3Y

14.8%5Y

Performance

36.3%1Y

50.3%3Y

54.1%5Y

Volatility